Clinical Trials Directory

Trials / Completed

CompletedNCT00555724

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

A Phase 1, Open Label, Dose Escalation Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Subjects With Relapsed or Refractory Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Biogen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGBIIB022IV infusion once every three weeks until disease progression or unacceptable toxicity

Timeline

Start date
2008-01-01
Primary completion
2010-04-01
Completion
2010-07-01
First posted
2007-11-09
Last updated
2017-01-09

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00555724. Inclusion in this directory is not an endorsement.